Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biofrontera (BFRI) EBITDA Margin (2020 - 2025)

Biofrontera (BFRI) has 6 years of EBITDA Margin data on record, last reported at 89.84% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 3480.0% year-over-year to 89.84%; the TTM value through Sep 2025 reached 47.41%, up 735.0%, while the annual FY2024 figure was 46.11%, 2044.0% up from the prior year.
  • EBITDA Margin reached 89.84% in Q3 2025 per BFRI's latest filing, down from 56.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.63% in Q4 2024 and bottomed at 371.6% in Q3 2021.
  • Average EBITDA Margin over 5 years is 74.62%, with a median of 56.29% recorded in 2025.
  • Peak YoY movement for EBITDA Margin: soared 28740bps in 2022, then crashed -13330bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 20.68% in 2021, then tumbled by -168bps to 55.4% in 2022, then soared by 34bps to 36.48% in 2023, then surged by 63bps to 13.63% in 2024, then crashed by -559bps to 89.84% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 89.84% in Q3 2025, 56.29% in Q2 2025, and 52.95% in Q1 2025.